Taysha gene therapies announces initiation of clinical development of tsha-118 for the treatment of cln1 disease

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced the initiation of clinical development of tsha-118 for the treatment of cln1 disease under a recently approved clinical trial application (cta). queen's university in ontari
TSHA Ratings Summary
TSHA Quant Ranking